Whole Body Hyperthermia and Intraperitoneal Carboplatin in Residual Ovarian Cancer

  • Justin D. Cohen
  • H. Ian Robins
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 267)


Intraperitoneal (IP) cisplatin-based chemotherapy provides prolonged disease-free survival in some women with residual peritoneal ovarian cancer following systemic chemotherapy. This review presents several considerations which support the combined use of IP carboplatin and whole body hyperthermia in this patient population. This novel treatment approach is predicated on projected advantages which relate to improved therapeutic index.


Ovarian Cancer Human Ovarian Carcinoma Cell Whole Body Hyperthermia Regional Hyperthermia Body Hyperthermia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrews, P.A., Velury, S., Mann, S.C., and Howell, S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48: 68–73, 1988.PubMedGoogle Scholar
  2. 2.
    Barlogie, B., Corry, P.M., and Drewinko, B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 40:1165–1168, 1980.PubMedGoogle Scholar
  3. 3.
    Calvert, A.H., Harland, S.J., Newell, D.R., Siddik, Z.H., Jones, A.C., McElwain, P.G., Raju, S., Wiltshaw, E., Smith, I.E., Baker, J.M., Peckham, M.J., and Harrap, K.R. Early clinical studies with cisdiammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother. Pharmacol. 9: 140–147, 1982.Google Scholar
  4. 4.
    Cohen, J.D., and Robins, H.I. Hyperthermie enhancement of cisdiammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro. Cancer Res. 47: 4335–4337, 1987.PubMedGoogle Scholar
  5. 5.
    Cohen, J.D., Robins, H.I., and Schmitt, C.L. Interactions of hyperthermia with carboplatin, cisplatin, and etoposide in human leukemia cells in vitro. Cancer Letters, in press.Google Scholar
  6. 6.
    Curt, G.A., Grygiel, J.J., Corden, B.J., Ozols, R.F., Weiss, R.B., Tell, D.T., Myers, C.E., and Collins, J.M. A Phase I and pharmacokinetic study of diamminecyclobutanedicarboxylatoplatinum (NSC 241240). Cancer Res. 43: 4470–4473, 1983.PubMedGoogle Scholar
  7. 7.
    Decker, D.G., Fleming, T.R., Malkasian, G.D. et al. Cyclophosphamide plus cisplatinum in combination: Treatment program for stage III or IV ovarian carcinoma. Obstetrics and Gynecology 60: 481–487, 1982.PubMedGoogle Scholar
  8. 8.
    Dedrick, R.L., Myers, C.E., Bungay, P.M., and DeVita, V.T. Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62: 1–11, 1978.PubMedGoogle Scholar
  9. 9.
    Eichholtz-Wirth, H., and Hietel, B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Brit. J. Cancer 54: 239–243, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Fisher, G., and Hahn, G.M. Enhancement of cis-platinum(II)diarrminedichloride cytotoxicity by hyperthermia. National Cancer Institute Monographs 61: 255–257, 1982.Google Scholar
  11. 11.
    Gerad, H., Egorin, M.J., Whitacre, M., Van Echo, D.A., and Aisner, J. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole body hyperthermia. Cancer Chemotherapy and Pharmacology 11: 162–166, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Howell, S.B., Pfeifle, C.L., Wung, W.E., Olshen, R.A., Lucas, W.E., Yon, J.L., and Green, M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Int. Med. 97: 845–851, 1982.Google Scholar
  13. 13.
    Howell, S.B., Zimm, S., Markman, M., Abramson, I.S., Cleary, S., Lucas, W.E., and Weiss, R.J. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J. Clin. Oncol. 5: 1607–1612, 1987.PubMedGoogle Scholar
  14. 14.
    Hugander, A., Robins, H.I., Martin, P., and Schmitt, C. Temperature distribution during radiant heat whole-body hyperthermia: experimental studies in the dog. Int. J. Hypertherm. 3: 199–208, 1987.CrossRefGoogle Scholar
  15. 15.
    Joss, R.A., Kaplan, S., Goldhirsch, A., Sessa, C., Brunner, K.W., and Cavalli, F. A Phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five-week schedule. Invest. New Drugs 2: 297–304, 1984.PubMedCrossRefGoogle Scholar
  16. 16.
    Koeller, J.M., Trump, D.L., Tutsch, K.D., Earhart, R.H., Davis, T.E., Tormey, D.C. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 57: 222–225, 1986.PubMedCrossRefGoogle Scholar
  17. 17.
    Kraker, A.J., and Moore, C.W. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. 48: 9–13, 1988.PubMedGoogle Scholar
  18. 18.
    Lambert, H.E., and Berry, R.J. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): Report from the North Thames Cooperative Group. Brit. Med. J. 290: 889–893, 1985.Google Scholar
  19. 19.
    Levin, L., and Hryniuk, W.M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 5: 756–767, 1987.PubMedGoogle Scholar
  20. 20.
    Markman, M., Cleary, S., and Howells, S.B. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur. J. Clin. Oncol. 21: 1015–1018, 1985.CrossRefGoogle Scholar
  21. 21.
    McVie, J.G., Dikhoff, T., Van der Heide, J., et al. Tissue concentra- tion of platinum after intraperitoneal cisplatin administration in patients. Abstract, Proc. Amer. Assoc. Cancer Res. 26: 162, 1985.Google Scholar
  22. 22.
    McVie, J.G., ten Bokkel Huinink, W.W., Dubbelman, R., Franklin, H., van der Vijgh, W., and Klein, I. Phase I study and pharmacokinetics of intraperitoneal carboplatin. Cancer Treat. Rev. 12: 35–41, 1985.Google Scholar
  23. 23.
    Meyn, R.E., Corry, P.M., Fletcher, S.E., and Demetriades, M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum (II). Cancer Res. 40: 1136–1139, 1980.PubMedGoogle Scholar
  24. 24.
    Myers, C.E. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Sem. Oncol. 11: 275–284, 1984.Google Scholar
  25. 25.
    Myers, C.E., and Collins, J.M. Pharmacology of intraperitoneal chemotherapy. Cancer Invest. 1: 395–407, 1983.PubMedCrossRefGoogle Scholar
  26. 26.
    Omura, G., Blessing, J.A., Ehrlich, C.E., et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57: 1725–1730, 1986.PubMedCrossRefGoogle Scholar
  27. 27.
    Ozols, R.F., Behrens, B.C., Ostchega, Y., and Young, R.C. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat. Rep. 12: 59–65, 1985.Google Scholar
  28. 28.
    Riviere, J.E., Page, R.L., Dewhirst, M.W., Tyczkowska, K., and Thrall, D.E. Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. Int. J. Hypertherm. 2: 351–358, 1986.CrossRefGoogle Scholar
  29. 29.
    Robins, H.I., Dennis, W.H., Neville, A.J., Shecterle, L.M., Martin, P.A., Grossman, J., Davis, T.E., Neville, S.R., Gillis, W.K., and Rusy, B.F. A nontoxic system for 41.8°C whole body hyperthermia: Results of a Phase I study using a radiant heat device. Cancer Res. 45: 3937–3944, 1985.PubMedGoogle Scholar
  30. 30.
    ten Bokkel Huinink, W.W., Dubbelman, R., Aartsen, E., Franklin, H., and McVie, J.G. Experimental and clinical results with intraperitoneal cisplatin. Sem. Oncol. 12: 43–46, 1985.Google Scholar
  31. 31.
    Thrall, D.E., Page, R.L., Dewhirst, M.W., Meyer, R.E., Hoopes, P.J., and Kornegay, J.N. Temperature measurements in normal and tumor tissue of dogs undergoing whole body hyperthermia. Cancer Res. 46: 6229–6235, 1986.PubMedGoogle Scholar
  32. 32.
    Wallner, K.E., DeGregorio, M.W., and Li, G.C. Hyperthermie potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 46: 6242–6245, 1986.PubMedGoogle Scholar
  33. 33.
    Wiltshaw, E., Evans, B., and Harland, S. Phase III randomised trial of cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV. Abstract, Proc. Amer. Soc. Clin. Oncol. 4: 121, 1985.Google Scholar
  34. 34.
    Wondergem, J., Bulger, R.E., Strebel, F.R., Newman, R.A., Travis, E.L., Stephens, L.C., and Bull, J.M.C. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res. 48: 440–446, 1988.PubMedGoogle Scholar
  35. 35.
    Zakris, E.L., Dewhirst, M.W., Riviere, J.E., Hoopes, P.J., Page, R.L., and Oleson, J.R. Pharmacokineties and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J. Clin. Oncol. 5: 1613 1620, 1987.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Justin D. Cohen
    • 1
  • H. Ian Robins
    • 2
  1. 1.Department of Human OncologyUniversity of WisconsinMadisonUSA
  2. 2.Departments of Human Oncology, Medicine, Neurology and Veterinary MedicineUniversity of WisconsinMadisonUSA

Personalised recommendations